# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for...
Argus Research analyst David Toung maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $300 to $340.
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...